NYSE:BHVN Biohaven Q3 2026 Earnings Results & Report $16.45 +0.93 (+6.02%) Closing price 03:59 PM EasternExtended Trading$15.98 -0.48 (-2.91%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Biohaven beat analyst earnings expectations in its Q3 2026 results, released October 29, 2026. The company reported EPS of -$0.73 versus the -$0.80 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 29, 2026TimeAfter Market ClosesConference Call7:00 AM ET Biohaven EPS ResultsActual EPS-$0.73Consensus EPS -$0.80Beat/MissBeat by +$0.07One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersBiohaven Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBiohaven's next earnings date is estimated for Monday, November 9, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Biohaven Q3 2026 Earnings FAQ Did Biohaven beat earnings estimates for Q3 2026? Biohaven (NYSE:BHVN) reported earnings of -$0.73 per share for Q3 2026, beating the consensus estimate of -$0.80. The report was announced on Thursday, October 29, 2026. When is Biohaven's next earnings date? Biohaven's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biohaven on the company's earnings history page. Biohaven Earnings HeadlinesEarnings Flash (BHVN) Biohaven Ltd. Posts Q3 Adjusted Loss $0.73 per Share, vs. FactSet Est of $-0.781 hour ago | marketscreener.comMBiohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsOctober 29 at 4:02 PM | prnewswire.com3 Stocks for AI’s Next WaveMarc Chaikin, a nearly 60-year market veteran, built the stock-rating system that flagged 43 of the market's top 50 stocks last year. He says the AI boom has moved in waves, from chipmakers to cooling and energy firms, with stocks like Celestica up over 3600% and Bloom Energy up more than 1230% in two years. Now his system points to three stocks positioned for AI's next wave.October 29 at 1:00 AM | Chaikin Analytics (Ad)RBC Capital Sticks to Its Hold Rating for Biohaven Ltd. (BHVN)October 28 at 12:06 AM | theglobeandmail.comBiohaven's BHV-1420 Targets PLA2R Autoantibodies In Membranous NephropathyOctober 28 at 9:02 AM | rttnews.comBiohaven Ltd. Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026October 26 at 4:34 PM | marketscreener.comMSee More Biohaven Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email. Email Address About BiohavenBiohaven (NYSE:BHVN) (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches. Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases. Its programs have included agents such as troriluzole, verdiperstat, BHV-7000 and BHV-1300, although candidates and development priorities may change as clinical studies progress. The company was founded by neurologist Vlad Coric, who serves as chief executive officer. In 2022, Pfizer acquired the commercial portfolio and certain other assets of the original Biohaven Pharmaceutical Holding Company, including the rights to Nurtec ODT and Zavzpret. A new, independent Biohaven was subsequently established to continue developing the company’s remaining pipeline and became publicly traded under the symbol BHVN.View Biohaven ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
